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Inflammation plays a key role in the development of colorectal cancers. We have investigated the relationship between PTGS2
(COX2) polymorphisms and colorectal cancer risk in a hospital based case–control study. We recruited 292 patients with colorectal
cancer and 274 controls from new patients admitted to Bellvitge Hospital, Barcelona, Spain, from 1996 to 1998. Subjects responded
to a questionnaire on risk factors. Genotypes of the eight more frequent polymorphisms of PTGS2 were determined. Two
polymorphisms are located in the promoter sequence, one in the untranslated region of exon 1, one in exon 3, one in intron 5, two
in the untranslated region of exon 10, and one downstream of the last polyadenylation (poly-A) signal. Associations were analysed
with logistic regression models assuming a dominant effect for rare variants to increase statistical power. An association was detected
between colorectal cancer and a polymorphism in the untranslated region of exon 10 of PTGS2, with an odds ratio (OR) of 2.49, 95%
confidence interval (CI) of 1.17–5.32, P¼ 0.01. A nearby polymorphism downstream of the last poly-A signal also showed a
nonsignificant increase in risk (OR 2.17, 95% CI 0.99–4.78, P¼ 0.05). Analysis of haplotypes confirmed that individuals with these
variants were at increased risk of colorectal cancer (OR compared to the most frequent haplotype: 2.17, 95% CI 0.97–4.84,
P¼ 0.06) Interactions between PTGS2 genotype and use of nonsteroidal anti-inflammatory drugs and risk of colorectal cancer were
also explored.
British Journal of Cancer (2004) 91, 339–343. doi:10.1038/sj.bjc.6601906 www.bjcancer.com
Published online 1 June 2004
& 2004 Cancer Research UK
Keywords: PTGS2/COX2; polymorphisms; colorectal cancer; gene–environment interaction





















































Inflammation is becoming a major area of interest in the
development and progression of many common cancers. Of
particular interest is the involvement of inflammation in colorectal
cancer. It is well established that inflammatory diseases of the
colon, such as Crohn’s disease and ulcerative colitis, substantially
increase the risk of colorectal cancer (Lennard-Jones et al, 1977;
Lashner et al, 1989; Rhodes and Campbell, 2002). Prostaglandins
are molecules of particular interest in the inflammatory response.
The cyclooxygenase (COX) enzymes, COX1 and COX2 (also known
as prostaglandin synthases (PTGSs), PTGS1 and PTGS2), are the
rate-limiting enzymes in the production of prostaglandins. PTGS2,
which is induced in the inflammatory response, is responsible for
the majority of prostaglandins present during the immune
response to inflammation. Nonsteroidal anti-inflammatory drugs
(NSAIDs) have been shown to protect against colorectal cancer
(Gupta and Dubois, 2001). While the mechanism of this protection
is still unclear, it can be hypothesised that it comes at least partly
from limiting either the activity of PTGS2, or the amount of the
enzyme present in the cell. It can also be hypothesised that genetic
polymorphisms in PTGS2 that result in alteration of the expression
and/or the activity of the protein may modulate the inflammatory
response, thus modifying the risk of colorectal cancer. While many
single-nucleotide polymorphisms (SNPs) have been identified in
the PTGS2 gene (Halushka et al, 1999; Cox et al, 2001), few have
been studied in terms of altering the function or expression of the
enzyme (Fritsche et al, 2001; Lin et al, 2002). Only one
polymorphism has been shown to alter the expression of PTGS2
(Papafili et al, 2002). In this study, we have explored the impact of
polymorphisms in PTGS2 on risk of colorectal cancer as well as
possible interactions between these polymorphisms and the use of
NSAIDs.
SUBJECTS AND METHODS
Study population
A case–control study was conducted to assess risk factors of
colorectal cancer. Cases were patients with a histologically
confirmed new diagnosis of colorectal cancer attending the
Bellvitge University Hospital in Barcelona, Spain, between January
of 1996 and December 1998. This study includes 292 cases that
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could be interviewed and provide biological samples of adequate
quality for genetic analyses.
Controls were randomly selected among patients admitted to the
same hospital during the same period. Sex and broad age groups
were used as stratifying criteria for frequency matching. From the
daily patient admission lists, candidate controls were approached
and, if they met these criteria, they were invited to participate. A
total of 274 controls were analysed in this study. To avoid selection
bias, the criterion for inclusion of controls was that the reason for
the current admittance to the hospital should be a new disease (not
previously diagnosed) for that patient. This criterion was used to
avoid inclusion of patients with chronic diseases, who might be
repeatedly admitted to hospital and modify their habits because of
their disease. This procedure paralleled the criterion for cases who
were also newly diagnosed incident cases. Both cases and controls
had to have good mental condition, and be able to see and hear
and follow an interview.
From a genetic point of view, we consider the hospitalised
controls as being representative of the general Spanish population,
as they came from very different hospital departments and
included very different diseases. Moreover, it was recently reported
in a pooled analysis with more than 15 000 controls from 73
different studies that the frequencies of genetic polymorphisms did
not differ between hospitalised and population controls (Garte
et al, 2001). No restriction criterion was imposed regarding the
diagnosis of controls except those previously mentioned. The
distribution of controls by diagnostic group was as follows:
internal medicine 22%, acute surgery 19%, urology 17%,
orthopedic surgery 15%, gastroenterology 16%, circulatory or
respiratory 11%. In all, 43 controls (16%) had a diagnosis of
inflammatory conditions that might be related to the studied
polymorphisms: inflammatory bowel disease (N¼ 2), peptic ulcer
(N¼ 2), pancreatitis (N¼ 17), cholecystitis (N¼ 16), arthritis
(N¼ 2) and diverticulitis (N¼ 4). We compared the distribution
of genotypes in this group and found no difference from the rest of
the controls. Also, an analysis of the data excluding these controls
yielded essentially the same results. Thus, we decided not to
exclude any control that had been selected.
Cases and controls were personally interviewed by trained
personnel using a structured questionnaire to determine demo-
graphic characteristics and potential risk factors for colorectal
cancer. Long-term drug use was included and the focus in this
analysis was on NSAIDs. Ever users were required to have
consumed the drug regularly during at least 6 consecutive months.
We analysed separately aspirin and other NSAIDs since in our
population aspirin is often taken irregularly or at very low doses
for secondary prevention of cardiovascular diseases, a fact that
may mask some effects. Life-long history of alcohol consumption
was collected through a structured questionnaire that requested
type of beverage, average daily amount and duration. Average
daily alcohol intake was estimated converting standard drink units
to grams of pure alcohol. Also, a dietary questionnaire was
administered that allowed estimation of total caloric intake.
All subjects were informed and gave written consent to
participate in the study and to allow their biological samples to
be genetically analysed, according to the Helsinki declaration. The
study protocol was cleared by the Ethical Committee of the
hospital.
SNP genotyping
We selected PTGS2 polymorphisms that were experimentally
confirmed to exist (in our laboratory or in the literature) and
that have sufficiently high frequency in Caucasians to allow a
meaningful analysis. Eight SNPs were thus chosen for the study.
Polymorphisms 401 and 926 (nomenclature of SNPs refers to base
numbers in GenBank entry D28235; NCBI dbSNP accession
numbers are reported in Table 2) are located in the promoter
sequence, 1629 in the untranslated region of exon 1, 3050 in exon
3, 5209 in intron 5, 8473 and 9850 in the untranslated region of
exon 10, and 10335 downstream of the last polyadenylation (poly-
A) signal.
Cases and controls were randomised on PCR plates, so that an
equal number of cases and controls could be analysed simulta-
neously. Polymorphisms 401, 3050, 5209, 8473 and 10335 were
genotyped with the Invader assay (Third Wave Technologies,
Madison, WI, USA). Polymorphisms 926 and 1629 were genotyped
with TaqMan technology (ABI, Foster City, CA, USA). Polymorph-
ism 9850 was genotyped by restriction enzyme digestion and
electrophoresis on agarose gels. All samples that did not give a
reliable result in the first round of genotyping were resubmitted to
up to three additional rounds of genotyping. Data points that were
still not filled after this procedure were left blank.
Sequences of primers and probes and experimental conditions
are available online at http://www-gan.iarc.fr/PTGS2_Genoty-
ping.html.
Data analysis
For genotype data obtained with Invader or TaqMan technology,
raw intensity counts were corrected with a negative control, and
the ratio between the two signals (one colour for each allele) was
used to call each genotype. Each polymorphism was tested in
controls to ensure that it fitted the Hardy–Weinberg equilibrium.
This was carried out using the Genotype Transposer (Cox and
Canzian, 2001) and Arlequin (Schneider et al, 2000) software.
PTGS2 haplotypes were reconstructed by use of the PHASE version
2 software (Stephens and Donnelly, 2003).
To test the hypothesis of association between risk factors and
genetic polymorphisms, multivariate methods based on logistic
regression analyses were used. When cases were subdivided into
groups by tumour site, polytomous logistic regression was used,
comparing each group of cases to the whole set of controls. All
analyses have been adjusted for age and sex. Odds ratios (OR) and
95% confidence intervals (CI) were calculated for each group. The
P-values have been derived from likelihood ratio tests. Special
attention was paid to explore the interactions between exposures
and genotype. These were tested adding a product term of both
variables (exposure and genotype) to the model that had the main
effects. To increase statistical power for low-frequency variants,
rare homozygotes were combined with heterozygotes assuming a
dominant effect since their risk estimates were similar but less
precise than the combination.
RESULTS
Characteristics of the study population and the association with
colorectal cancer are presented in Table 1. In this study, we find
high risk of colorectal cancer associated to family history of
colorectal cancer and to a lower extent of other cancers. Other risk
factors are total energy intake and alcohol intake. Protective
factors are high parity for women and long-term NSAID use. Use
of NSAIDs in general was associated with significant reduction in
risk. However, the reduction was stronger for NSAIDs other than
aspirin. Use of aspirin alone was associated with a reduction in
risk, but this observation was not statistically significant (Table 1).
All polymorphisms were in Hardy–Weinberg equilibrium. Tests
for linkage disequilibrium (LD) between the polymorphisms
showed that extensive LD exists along the entire gene (data not
shown). Allele frequencies for all polymorphisms studied ranged
from 1% for PTGS2.1629 to 31% for PTGS2.8473. We found that, in
this sample set, carriers of the G allele of PTGS2.9850 had a
significantly increased risk of colorectal cancer, with an OR,
adjusted for age and sex, of 2.49 (95% CI 1.17–5.32; P-
value¼ 0.015). The minor allele of the SNP nearby, PTGS2.10335,
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was also associated with increased risk, with an OR of 2.17,
approaching statistical significance (95% CI 0.99–4.78, P¼ 0.05).
Other polymorphisms studied were not related to colorectal
cancer. The frequencies for each genotype or combination of
genotypes and the corresponding odds ratios can be seen in
Table 2. The ORs were similar for men and women when analysed
separately and also when cases were split according to tumour
localisation (colon vs rectum) (data not shown).
To further elucidate the relevance of PTGS2 SNPs, haplotypes
for the eight PTGS2 SNPs were reconstructed using PHASE
software (Stephens and Donnelly, 2003). In total, 24 distinct haplo-
types were found, six of which with frequencies higher than 1% in
the controls. The results are reported in Table 3 and showed that
the haplotype effects essentially coincide with the effect of
PTGS2.9850 and PTGS2.10335 alleles alone. Indeed, the only
haplotype that approaches statistical significance (OR¼ 2.17, 95%
CI 0.97–4.84, P¼ 0.06) is the one that carries the variant alleles of
these two polymorphisms (Table 3).
We explored the relationship between PTGS2 polymorphisms
and exposure to NSAIDs, since these have been shown both to
inhibit PTGS2 action in vitro and to protect from colorectal cancer.
Previous long-term exposure to NSAIDs was clearly protective by
Table 1 Characteristics of cases and controls
Cases/controls ORa 95% CI P-valueb
Sex
Male 173/140 1
Female 119/134 0.73 (0.52–1.02)
Age (years)
(24, 62) 86/100 1
(62, 73) 106/79 1.08 (0.53–2.17)
(73, 92) 100/95 1.07 (0.38–2.99)
Family history
No relatives with cancer 137/152 1 0.001
Colon cancer 44/16 3.10 (1.65–5.81)
Other cancers 111/106 1.26 (0.88–1.81)
Body mass index (BMI)
(16.0, 24.5) 107/78 1 0.21
(24.5, 27.6) 85/100 0.59 (0.39–0.90)
(27.6, 40.7) 93/92 0.72 (0.47–1.11)
Smoking status
Non-smoker 151/157 1 0.61
Ex-smoker 91/65 1.11 (0.65–1.88)
Smoker 50/52 0.85 (0.48–1.49)
Smoking duration (years)
Never 151/157 1 0.42
1–40 62/67 0.81 (0.47–1.38)
440 79/50 1.24 (0.71–2.17)
Alcohol daily intake (grams pure alcohol)
Never 100/123 1 0.015
1–60 141/125 1.46 (0.94–2.25)
460 51/26 2.69 (1.41–5.16)
Alcohol duration (years)
Never 100/123 1 0.014
1–40 70/77 1.19 (0.73–1.94)
440 122/74 2.00 (1.23–3.27)
Daily energy intake (kcal)
(530, 1636) 81/104 1 0.017
(1636, 2266) 99/86 1.45 (0.94–2.23)
(2266, 5295) 105/80 1.68 (1.05–2.70)
Any NSAIDc
Never 238/198 1 0.004
Ever 54/76 0.55 (0.37–0.83)
Aspirinc
Never 249/227 1 0.32
Ever 43/47 0.79 (0.50–1.25)
NSAID no aspirinc
Never 276/232 1 0.0001
Ever 16/42 0.31 (0.17–0.58)
Parity in women
Nulliparous 20/7 1 0.014
1 19/14 0.51 (0.17–1.56)
2–3 51/79 0.24 (0.09–0.61)
X4 29/34 0.34 (0.12–0.93)
aOdds ratios adjusted for age and sex. bP-values for trend except family history and
smoking status. cEver users were required to have consumed the drug regularly
during at least 6 consecutive months. NSAIDs¼ nonsteroidal anti-inflammatory
drugs; 95% CI¼ 95% confidence interval.
Table 2 Genotype counts for PGTS2 polymorphisms and odds ratios
(ORs) for colorectal cancer
Cases/controlsa ORb 95% CI P-value
PTGS2.401 (rs689465)c
A/A 201/181 1 0.83
A/G 67/69 0.92 (0.62–1.38)
G/G 9/9 0.78 (0.3–2.05)
PTGS2.926 (rs20417)
G/G 150/170 1 0.87
G/C 59/77 0.92 (0.61–1.39)
C/C 11/10 1.13 (0.46–2.80)
PTGS2.1629 (rs20424)
C/C 280/263 1 0.38
C/G–G/G 10/6 1.59 (0.56–4.52)
PTGS2.3050 (rs5277)
G/G 180/183 1 0.29
G/C 97/79 1.3 (0.9–1.87)
C/C 13/10 1.5 (0.63–3.57)
PTGS2.5209 (rs20432)
T/T 187/174 1 0.96
T/G 91/86 1.05 (0.73–1.52)
G/G 12/11 0.99 (0.42–2.33)
PTGS2.8473 (rs5275)
T/T 140/126 1 0.99
T/C 121/120 1.01 (0.71–1.45)
C/C 29/25 1.05 (0.58–1.91)
PTGS2.9850 (rs4648298)
A/A 257/258 1 0.01
A/G–G/G 24/10 2.49 (1.17–5.32)
PTGS2.10335 (rs689469)
G/G 245/241 1 0.05
G/A–A/A 20/10 2.17 (0.99–4.78)
aFor some polymorphisms, numbers do not sum up to the totals of controls or cases
due to genotyping failure. All samples that did not give a reliable result in the first
round of genotyping were resubmitted to up to three additional rounds of
genotyping. Data points that were still not filled after this procedure were left blank.
bOdds ratio adjusted for age and sex. For the low-frequency variants, rare
homozygotes have been combined with heterozygotes since their risk estimates
were similar but less precise than the combination. cNomenclature of single-
nucleotide polymorphisms (SNPs) refers to base numbers in GenBank entry D28235.
NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) accession numbers are reported in
parentheses. 95% CI¼ 95% confidence interval.
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itself, especially for NSAIDs different from aspirin (Table 1).
Although no statistically significant interaction with PTGS2.9850
polymorphism was observed (P-value¼ 0.19), the protective effect
of NSAIDs observed for the wild-type homozygous genotype (OR
for AA¼ 0.55; 95% CI 0.36–0.84) disappeared among those with
the variant allele for the polymorphism (OR for AG/GG¼ 1.08,
95% CI 0.17–6.77), since the few exposed with the variant had the
same increased risk as those not exposed. The numbers of subjects
carrying the variant with NSAID exposure were however very small
(six cases and two controls, compared to 18 cases and eight
controls not exposed to NSAIDs) and no firm conclusion can be
drawn on this point.
DISCUSSION
In this study, we have found an increased risk for colorectal cancer
associated with polymorphisms in PTGS2, a gene triggered by the
inflammatory response, and governing the synthesis of prosta-
glandins. Only one polymorphism, at base pair 9850 in GenBank
sequence D28235, showed a significant increase in risk. Poly-
morphism PTGS2.10335 also showed a marginally significant
association, but PTGS2.9850 and PTGS2.10335 were in tight LD
(r2¼ 0.79), and we will focus our discussion on 9850, as it is before
the poly-A signal, and therefore more likely to have a functional
relevance, while 10335 is after. This provides further evidence in
the case for the involvement of inflammation as a mechanism of
sporadic colorectal cancer.
While the polymorphisms in PTGS2 have been known to exist
for a few years, only one has so far been proven to have any
functional effect (Papafili et al, 2002). In our study, however, this
polymorphism (located at base 926 of GenBank sequence D28235)
failed to show an association with colorectal cancer risk. It may be
that the acute-phase response that was found associated to this
polymorphism is not relevant for long-term mechanisms leading
to colorectal carcinogenesis. In addition, a rare variant Val511Ala
was reported to be weakly associated with colorectal neoplasia and
predicted to modify the conformation of the PTGS2 enzyme (Lin
et al, 2002). However, this polymorphism is absent in Caucasians
and therefore was not included in our study.
The polymorphism at base pair 9850 is located approximately
100 base pairs upstream of the first poly-A signal in PTGS2. It can
be speculated that this polymorphism has some effect on the
addition of the poly-A tail to the mRNA, or causes a later poly-A
site to be used, creating a longer, and possibly more stable species
of mRNA. An alternative explanation is that it is in LD with other
functional polymorphisms nearby. However, we have explored all
known frequent polymorphisms of PTGS2, up to the SNP located
at base 10335, which is downstream of the last polyadenylation
site, and the polymorphism at base pair 9850 shows the strongest
association. We consider therefore the LD explanation quite
unlikely. We have performed haplotype analysis and we believe it
reinforces our conclusion on the LD explanation. Indeed, only one
haplotype was associated with increased risk, and this is also the
only one that carries the two at-risk alleles of SNPs PTGS2.9850
and PTGS2.10335. Had susceptibility been due to another, yet
unidentified polymorphism, we should have observed some
increase of risk associated also with other haplotypes, which is
not the case. Alternatively, one should postulate the existence of an
unknown causal polymorphism in perfect allelic association with
PTGS2.9850 (i.e. with exactly the same frequency). Such poly-
morphism could be found by sequencing the entire region between
PTGS2.9850 and PTGS2.10335, and some stretch of sequence
upstream and downstream of the two SNPs, in the 20 cases who
carry the at-risk haplotype (Table 3). Given that we are dealing
with the 30UTR of the gene, a straightforward interpretation of SNP
function cannot be provided by simple analysis of the sequence.
Therefore, functional tests should be performed to evaluate
PTGS2.9850 and any other polymorphism that may be found in
the region, in LD with PTGS2.9850.
Finally, we have investigated protection from colorectal cancer
by NSAIDs and whether it might be modulated by PTGS2
polymorphisms. Nonsteroidal anti-inflammatory drugs have re-
peatedly been shown to be protective against colorectal cancer
(Gupta and Dubois, 2001). In this study, we find the protective
effect stronger for NSAIDs different from aspirin. We attribute this
to the fact that aspirin is often consumed at low doses either for
sporadic pain relief or for cardiovascular indications. This
occasional consumption may be insufficient to confer protection
for colorectal cancer. Other NSAIDs, if consumed during a long
period as requested in our interview, may have greater preventive
potential since the anti-inflammatory power is greater at the doses
usually consumed. Although the OR estimates show that the
protective effect of NSAIDs disappears for those with the variant
allele at PTGS2.9850, the interaction is not significant, since the
prevalence of NSAIDs exposure is low and combined with the low
allele frequency of the variant results in very wide CIs. The
hypothesis that protection from colorectal cancer by NSAIDs use
might be counteracted by the genetic variant at base 9850 is
intriguing. Data from this study can just suggest it but not
confirm due to insufficient sample size to study this interaction in
detail.
There are several difficulties to face in interpreting the results of
case–control studies that explore gene–environment interactions.
As in any case–control study, there are limitations involved,
like potential selection bias from low participation rates, recall
bias, and difficulty in assessing past exposures. We recognise
that hospital controls are convenient to get biological material
from but are not ideal to recall exposures. We have tried to
minimise this potential bias with a careful design, but this may
have not been enough. The questionnaire was structured and
administered by trained interviewers. From a genetic point of view,
we consider the hospitalised controls as being representative of the
general Spanish population, as they came from very different
hospital departments and included very different diseases. We
believe that the impact of hospital controls on the polymorphism
status should be minimal, as recently suggested (Garte et al, 2001).
Moreover, if the proinflammatory allele was related to other
diseases that induced hospital admissions, this should have
increased its prevalence among controls and biased the ORs
towards the null.
In conclusion, we have detected weak associations between
several PTGS2 polymorphisms and risk of colorectal cancer, which
reach statistical significance for polymorphism PTGS2.9850
Table 3 Relative risk of colorectal cancer in relation to PTGS2 haplotypes
PTGS2 haplotypea Cases/controlsb ORc (95% CI) P-value
AGCGTTAG 275/268 1
AGCCTTAG 113/89 1.24 (0.89–1.71) 0.20
GCCGGCAG 89/89 0.97 (0.69–1.37) 0.83
AGCGTCAG 62/66 0.92 (0.62–1.35) 0.65
ACCGGCGA 20/9 2.17 (0.97–4.84) 0.06
AGGCTTAG 10/6 1.62 (0.58–4.53) 0.35
GCCGGTAG 2/4 0.49 (0.09–2.68) 0.41
GGCGGCAG 1/2 0.49 (0.04–5.41) 0.56
GCCGTTAG 1/1 0.97 (0.06–15.7) 0.99
Rared 12/14 0.84 (0.38–1.84) 0.66
aThe order of single-nucleotide polymorphisms (SNPs) in the haplotypes is
PTGS2.401–PTGS2.926–PTGS2.1629–PTGS2.3050–PTGS2.5209–PTGS2.8473–
PTGS2.9850–PTGS2.10335. bNumber of chromosomes in each group (double the
number of subjects). cOdds ratio and 95% confidence interval (95% CI). dRare
haplotypes (frequency p0.5%) that were found only among cases or only among
controls.
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(OR¼ 2.49). Possible interactions between this polymorphism and
intake of NSAIDs were also detected. The association of PTGS2
polymorphism with colorectal cancer points towards the implica-
tion of inflammation as an important mediator in the carcinogen-
esis of these tumours. It is worth confirming these findings in
other settings and carry out functional studies of the polymorph-
ism.
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